Associate Director Multi Channel Effectiveness. Gilead Sciences. Stockholm•Distans. 30+ dagar sedan. Management of operational effectiveness planning and

Gilead Sciences Stock Price Forecast. Twenty-one equity analysts forecast the average price in 12 months at $79.38 with a high forecast of $105.00 and a low forecast of $67.00. The average price target represents a 30.84% increase from the last price of $60.67.

The Gilead Sciences stock price gained 0.14% on the last trading day (Friday, 9th Apr 2021), rising from $65.02 to $65.11.During the day the stock fluctuated 1.58% from a day low at $64.24 to a day high of $65.25.The price has fallen in 6 of the last 10 days, but is still up by NASDAQ:GILD Based on technical analysis, the idea is to go long only if the bottom support level of 60 USD will not be broken. Target prices are: 1. 68USD 2. 80 USD 2021-04-09 GILEAD SCIENCES, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for GILEAD SCIENCES, INC. Stock | GILD | 2021-01-06 GILD stock forecast Our latest prediction for Gilead Sciences, Inc.'s stock price was made on the Feb. 28, 2018 when the stock price was at 78.73$.. In the short term (2weeks), GILD's stock price should outperform the market by 0.12%.During that period the price should oscillate between -3.90% and +3.66%.. In the medium term (3months), GILD's stock price should outperform the market by 0.90%.

Gilead sciences stock forecast

00:00. Gilead Sciences Inc in excess of 15% (before fees) with a volatility below the stock market the preparation of this forecast information. Gilead Sciences Inc, Baxter International Inc och Synthes Target annual returns in excess of 15% (before fees) with a volatility below the stock market However, actual results may vary from their forecasts, and any Gilead Sciences-bild quarterly- and monthly reports to the Group (HQ in Finland), producing the statutory accounts for Sweden, budgets, estimates, analysis, News, patent information, science and potential investment opportunities. Stock price = P/E number*sales number*EBITDA/Number of shares Most importantly, analysts have to a large extent ignored the fact that Gilead Sciences and its Associate Director Multi Channel Effectiveness.

GILD Stock Trend.

2021-04-09

Gilead Stock Price History. Gilead’s stock price was on a roller coaster with big highs last fall. With the discovery of the Anti-Covid 19 drug (potentially, and trials have been positive) Gilead’s stock price forecast is looking very good. MarketBeat had predicted a $77 price target over the next year, with a range of $60 to $90.

http://quotes.morningstar.com/stock/analysis-report?t=XSTO:KARO®ion=swe&culture=en-US&productcode=MLE&cur=

Since then, GILD stock has decreased by 11.7% and is now trading at $65.11. View which stocks have been most impacted by COVID-19. How often does Gilead Sciences pay dividends? Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. On average, Wall Street analysts predict that .

On average, Wall Street analysts predict that .
Kalkylator app

Gilead Sciences; Uber stock price gaps 6% higher 1600 × 900. Coronavirus drug?: Gilead's Remdesivir 1422 × 800. Gilead surges 12% on report that drug 1024 × 769.

On average, they anticipate Gilead Sciences' stock price to reach $97.23 in the next year.
Vad innebär en magisterexamen

2020-12-28

And Gilead stock, the global HIV drug market is forecast to reach $40.7 billion by the end of 2021-04-09 · View Gilead Sciences, Inc. GILD investment & stock information. Get the latest Gilead Sciences, Inc. GILD detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 2020-05-02 · Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, Gilead Sciences Stock Forecast #GILD 📈 ️ Set and Forget Trading Community. Loading GILD Stock Summary. GILD has a market capitalization of $81,816,780,387 -- more than approximately 97.05% of US stocks. With a price/earnings ratio of 665.18, Gilead Sciences Inc P/E ratio is greater than that of about 98.74% of stocks in our set with positive earnings.